IceCure Medical announces interim results from ICESECRET study

IceCure Medical (ICCM) announced that interim results from the Company’s ICESECRET study of cryoablation for patients with small renal masses who cannot be offered kidney preserving surgery were presented at the European Association of Urology Conference in Madrid, Spain which took place March 21-24, 2025. “We are very pleased to see these impressive data shared at a major urology conference in Europe, where ProSense is approved for renal tumors” stated Eyal Shamir, IceCure’s Chief Executive Officer. “These data support the adoption of cryoablation as a safe and effective option for patients who are otherwise ineligible for kidney preserving surgery, a large unmet need.” Conclusions and data in the presentation included the following: Cryoablation is a viable alternative for SRMs, especially for tumors less than or equal to3 cm; 111 patients were evaluated at a mean follow-up of approximately 3 years; Recurrence free rate was 88.7% in patients with tumors less than or equal to3 cm, low risk and a successful procedure at a mean follow up of 3.4 years; Recurrence free rate was 87.8% in patients with tumors less than or equal to3 cm at low risk with at a mean follow up of 3.4 years; Recurrence free rate was 87.2% in patients with tumor size less than or equal to3 cm at a mean follow up of 3.5 years; Safety results include 17 mild adverse events, 3 moderate events, and 1 severe complication observed; and The mean age of the patients was 69 and 84.2% had comorbidities, the most common of which were hypertension and diabetes.